人工智能软件Cohere收购Reliant AI，以扩大面向全球生物制药和医疗保健行业的主权企业人工智能业务-动脉网

Cohere acquires biopharma AI specialist Reliant AI

D-Pharm 等信源发布 2026-05-28 13:09



可切换为仅中文







Cohere announced the acquisition of Reliant AI, a biopharma AI company with operations in Montreal and Berlin. This acquisition brings Reliant AI’s world-class research team, proprietary biomedical datasets, and domain-optimized technology into Cohere’s enterprise-grade sovereign AI platform. This significantly expands Cohere’s footprint in the global healthcare and life sciences sectors–where security, data privacy, and regulatory compliance are paramount—and builds on Cohere’s existing partnerships across administrative, clinical, and revenue cycle workflows..

Cohere 宣布收购 Reliant AI，这是一家在蒙特利尔和柏林设有业务的生物制药 AI 公司。此次收购将 Reliant AI 世界一流的科研团队、专有的生物医学数据集以及领域优化的技术整合到 Cohere 的企业级主权 AI 平台中。此举大幅扩展了 Cohere 在全球医疗保健和生命科学领域的影响力——在这些领域，安全性、数据隐私和监管合规至关重要——同时也进一步巩固了 Cohere 在行政、临床和收入周期工作流程方面的现有合作伙伴关系。

The acquisition strengthens Cohere’s position as sovereign AI leader, building on its established presence in Canada and Germany and growing momentum across Europe. Together, Cohere and Reliant AI will equip healthcare and life sciences enterprises with a powerful combination of cutting-edge AI technology, secure deployment options for highly regulated environments, and deep domain expertise to improve processes and bring projects to market faster.

此次收购巩固了Cohere作为主权AI领导者的地位，基于其在加拿大和德国的已有影响力，并在欧洲范围内不断扩大势头。Cohere与Reliant AI将共同为医疗保健和生命科学企业提供尖端AI技术、适用于高度监管环境的安全部署选项以及深厚的领域专业知识的强大组合，以改进流程并加速项目上市。

This ensures enterprises and governments worldwide can deploy advanced models and systems with full control over their data, infrastructure, and compliance boundaries..

这确保了全球企业和政府能够在完全掌控其数据、基础设施和合规边界的情况下部署先进模型和系统。

“We’re excited to welcome the Reliant AI team to Cohere as we deepen our work across healthcare and biopharma,” said Aidan Gomez, Co-founder and CEO, Cohere. “Healthcare represents one of the most consequential opportunities for AI and it demands secure, sovereign, and domain-specific systems. Together, we will accelerate progress in healthcare, building on our shared footprint across Canada and Germany to serve these critical sectors.

“我们很高兴欢迎Reliant AI团队加入Cohere，因为我们正在深化在医疗保健和生物制药领域的工作，”Cohere的联合创始人兼首席执行官Aidan Gomez表示。“医疗保健是AI最具意义的机会之一，它需要安全、自主且特定领域的系统。我们将共同努力，加速医疗保健领域的进展，基于我们在加拿大和德国的共同基础，为这些关键领域提供服务。”

We look forward to bringing North for Pharma to customers and partners as a cornerstone in our expanding portfolio of industry-specific AI products.”.

我们期待将North for Pharma带给客户和合作伙伴，作为我们不断扩展的行业专用AI产品组合中的基石。”

Using algorithms to track down cancer

利用算法追踪癌症

Read news

阅读新闻

Reliant AI’s flagship product is an intelligent research workbench used by global biopharma organizations to automate systemic literature reviews, competitive landscaping, and extraction of unstructured scientific and regulatory data. The platform also enables rapid identification of therapeutic precedents and modelling of market viability, dramatically accelerating decision-making and time to market..

Reliant AI 的旗舰产品是一款智能研究工作台，被全球生物制药组织用于自动化系统文献综述、竞争格局分析以及提取非结构化的科学和监管数据。该平台还能够快速识别治疗先例并模拟市场可行性，大幅加速决策过程和上市时间。

Reliant was founded in 2023 by Karl Moritz Hermann, Richard Schlegel and Marc G. Bellemare (Canada CIFAR AI Chair, Mila).

Reliant 由 Karl Moritz Hermann、Richard Schlegel 和 Marc G. Bellemare（加拿大 CIFAR AI 主席，Mila）于 2023 年创立。

'Joining Cohere represents a transformative opportunity to scale our biopharma AI solutions globally while maintaining the security and sovereignty that life sciences organizations require,” said Karl Moritz Hermann, CEO of Reliant AI. “Our combined expertise will accelerate drug discovery and research innovation for customers around the world.”.

“加入Cohere代表了一个转型的机会，可以在全球范围内扩展我们的生物制药AI解决方案，同时满足生命科学组织所需的安全性和主权，”Reliant AI首席执行官Karl Moritz Hermann表示。“我们的综合专业知识将加速全球客户的药物发现和研究创新。”

By integrating these capabilities, Cohere will accelerate the development of North for Pharma, an agentic AI system purpose-built to enhance productivity and efficiency for teams in the biopharma sector working across R&D, clinical development, and scientific analytics. North for Pharma extends Cohere’s growing suite of North offerings for regulated industries, including finance and telecoms.

通过整合这些能力，Cohere将加速开发面向制药行业的North系统，这是一种专为提升生物制药领域团队在研发、临床开发和科学分析方面生产力和效率而构建的代理AI系统。North for Pharma拓展了Cohere针对受监管行业（包括金融和电信）不断增长的North产品系列。

Reliant AI co‑founder and CEO Karl Moritz Hermann will join Cohere as VP of AI Verticalizations in Berlin, while fellow co‑founder Marc Bellemare will serve as VP of Modeling from Montreal..

Reliant AI 联合创始人兼首席执行官卡尔·莫里茨·赫尔曼将加入 Cohere，担任柏林的 AI 垂直化副总裁，而另一位联合创始人马克·贝尔马尔将从蒙特利尔出任建模副总裁。

The deal further unlocks new opportunities across the sector with specialized AI models and solutions tailored to pharmaceutical and biotechnology workflows–addressing challenges that general-purpose AI cannot. As part of the agreement, Cohere will assume Reliant AI’s customer relationships, including GSK, Medicus Pharma, and Kyowa Kirin, and will continue on advancing Reliant AI’s ongoing engagements with major pharmaceutical companies..

该交易进一步释放了整个行业的全新机遇，提供专门针对制药和生物技术工作流程定制的专业人工智能模型和解决方案，解决通用人工智能无法应对的挑战。根据协议，Cohere将接管Reliant AI的客户关系，包括GSK、Medicus Pharma和协和麒麟（Kyowa Kirin），并将继续推进Reliant AI与主要制药公司的持续合作。

https://www.bionity.com/en/news/1188778/cohere-acquires-biopharma-ai-specialist-reliant-ai.html

5 million euros for digital health start-up

500万欧元用于数字健康初创公司

For the first time, Patient-Reported Outcome Measures are systematically linked to clinical data to improve treatment and research

首次将患者报告的结果指标系统地与临床数据联系起来，以改进治疗和研究。

Read news

阅读新闻